EBOS Group Limited posted robust interim results for H1 FY25, with underlying EBITDA rising 7.1% excluding the Chemist Warehouse Australia contract, driven by strong organic growth and strategic investments. The company maintained its dividend and reiterated FY25 EBITDA guidance between $575 million and $600 million.
Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.
CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.
CurveBeam AI has broadened its commercial agreement with Stryker to cover Australia and New Zealand, aiming to accelerate adoption of its HiRise weight bearing CT scanners through targeted surgeon education and promotion.
PolyNovo Limited reports a robust 22.8% revenue increase in 1H FY25, driven by strong U.S. and international sales growth and progressing FDA approval efforts for its NovoSorb platform.